良性指征子宫切除术中同期行顶端支持手术的成本效益分析
本研究采用 Markov 决策模型,从医疗保健部门角度比较良性指征子宫切除术同期行顶端支持(McCall 阴道穹隆成形术)与单纯子宫切除术的成本效益,模拟 3 年。结果显示同期顶端支持成本更高(1667 美元 vs 1423 美元)但更有效(2.34 vs 2.31 QALYs),增量成本效益比为 11988 美元/QALY,在敏感性分析中仍具成本效益。
要点
- 同期顶端支持成本 1667 美元 vs 单纯子宫切除 1423 美元,QALYs 2.34 vs 2.31。
- 增量成本效益比 11988 美元/QALY,低于一般支付意愿范围 50000-150000 美元/QALY。
- 只要同期顶端支持术后 prolapse 率低于 8.7%,仍具成本效益。
核心结论
- 从医疗保健部门角度、3 年时间范围内,良性指征子宫切除术同期行顶端支持与单纯子宫切除术相比具有成本效益。
- 作者认为鼓励子宫切除术同期行顶端支持手术是预防术后阴道 prolapse 的成本效益策略。
研究设计与样本
- 研究采用 Markov 决策模型,从医疗保健部门角度比较良性指征子宫切除术同期行顶端支持(即 McCall 阴道穹隆成形术)与单纯子宫切除术。
- 模型模拟无症状、未治疗 prolapse 和治疗后 prolapse 三种状态间 3 年的 Markov 转换。
- 主要结局为增量成本效益比,即组间平均成本(2019 年美元)差值除以平均质量调整生命年(QALY)差值。
- 模型参数估计来自已发表的医学文献,成本估计来自 Medicare 报销率和文献。
- 进行了单因素、双因素和概率敏感性分析。
主要发现
- 基础病例场景假设单纯子宫切除术后 prolapse 率为 13%,同期顶端支持后为 2.1%;后续接受手术治疗的比例分别为 5.8% 和 0.9%。
- 同期顶端支持成本更高(1667 美元 vs 1423 美元),但更有效(2.34 vs 2.31 QALYs)。
- 同期顶端支持的增量成本效益比为 11988 美元/QALY,一般支付意愿范围为 50000-150000 美元/QALY。
- 敏感性分析显示,只要同期顶端支持后 prolapse 率低于 8.7%,同期顶端支持仍具成本效益。
- Monte Carlo 模拟显示,同期顶端支持在超过 60% 的模拟迭代中具有成本效益。
关键数值与推荐
- 基础病例场景:单纯子宫切除术后 prolapse 率 13%,同期顶端支持后 2.1%;后续手术治疗率分别为 5.8% 和 0.9%。
- 同期顶端支持成本 1667 美元 vs 单纯子宫切除 1423 美元;QALYs 2.34 vs 2.31。
- 增量成本效益比 11988 美元/QALY,一般支付意愿范围 50000-150000 美元/QALY。
- 敏感性分析中,同期顶端支持后 prolapse 率阈值低于 8.7% 时仍具成本效益。
- Monte Carlo 模拟中同期顶端支持在超过 60% 的迭代中具成本效益。
临床怎么用
- 作者认为鼓励子宫切除术同期行顶端支持手术是预防术后阴道 prolapse 的成本效益策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the cost effectiveness of performing routine concurrent apical support procedures at the time of hysterectomy for benign indications. METHODS: We developed a Markov decision model from the health care sector perspective to compare concurrent apical support (ie, McCall culdoplasty) at the time of hysterectomy for benign indications compared with hysterectomy alone. We modeled Markov transitions between asymptomatic, prolapse without treatment, and treated prolapse states for 3 years. Our primary outcome was incremental cost-effectiveness ratio, defined as the difference between groups in mean cost (2019 U.S. dollars) divided by the difference in mean quality-adjusted life-years (QALYs). Model parameter estimates were taken from the published medical literature. Cost estimates were obtained from Medicare reimbursement rates and the literature. One-way, two-way, and probabilistic sensitivity analyses were performed. RESULTS: We assumed a base-case scenario of 13% posthysterectomy prolapse after hysterectomy alone and 2.1% after concurrent apical support, 5.8% and 0.9% undergoing subsequent surgical treatment for prolapse, respectively. Concurrent apical support at the time of hysterectomy had higher costs ($1,667 vs $1,423) but was more effective (2.34 vs 2.31 QALYs) than hysterectomy alone. Concurrent apical support was cost effective with an incremental cost-effectiveness ratio of $11,988/QALY, compared with general willingness-to-pay ranges of $50,000-150,000/QALY. In sensitivity analyses, concurrent apical support remained cost effective as long as the rate of posthysterectomy prolapse after concurrent apical support remained less than 8.7%. Monte Carlo simulation showed that concurrent apical support was cost effective in more than 60% of the simulated iterations. CONCLUSION: Apical support at the time of hysterectomy for benign indications is cost effective compared with hysterectomy alone from the health care sector perspective at 3 years. Our results suggest that encouraging concurrent apical support procedures at time of hysterectomy is a cost-effective strategy in preventing posthysterectomy vaginal prolapse.
引用
- Wang R, Tulikangas P, Harvie HS, et al. Apical Support Procedures at the Time of Hysterectomy for Benign Indications: A Cost-Effectiveness Analysis. Obstet Gynecol. 2022. PMID: 35576338. doi:10.1097/AOG.0000000000004764
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。